about
Antituberculosis therapy for 2012 and beyondTuberculosis therapy for 2016 and beyond.HIV protease inhibitors: advances in therapy and adverse reactions, including metabolic complications.Tolerance and pharmacokinetic interactions of rifabutin and clarithromycin in human immunodeficiency virus-infected volunteers.Pharmacokinetic Interaction between amprenavir and rifabutin or rifampin in healthy malesEffect of rifampin and rifabutin on the pharmacokinetics of lersivirine and effect of lersivirine on the pharmacokinetics of rifabutin and 25-O-desacetyl-rifabutin in healthy subjects.Drug-induced uveitisIntracellular time course, pharmacokinetics, and biodistribution of isoniazid and rifabutin following pulmonary delivery of inhalable microparticles to mice.New drugs against tuberculosis: problems, progress, and evaluation of agents in clinical development.Metabolism of rifabutin and its 25-desacetyl metabolite, LM565, by human liver microsomes and recombinant human cytochrome P-450 3A4: relevance to clinical interaction with fluconazole.Antimicrobial activities of cinnamyl rifamycin derivatives, T-9 and T-11, against Mycobacterium tuberculosis and Mycobacterium avium complex (MAC) with special reference to the activities against intracellular MAC.Bilateral uveitis associated with concurrent administration of rifabutin and nelfinavir.Induction of influx and efflux transporters and cytochrome P450 3A4 in primary human hepatocytes by rifampin, rifabutin, and rifapentine.Corneal endothelial deposits secondary to rifabutin prophylaxis for Mycobacterium avium complex bacteraemia.Induction of hepatic and presystemic metabolism of antipyrine in the mice: rifampicin versus rifabutin.Pharmacokinetics and dosage adjustment of rifabutin in a haemodialysis patient.
P2860
Q26829101-159753C7-8729-4352-AEF5-196D1311AB95Q30248788-DFAC17E5-5F98-4C90-A727-D866206FCDB6Q33604216-42EFBD02-71D8-469D-972D-9C76273621D5Q33691292-9FBF710A-80D8-4C1C-936C-8DE85F312782Q33981408-48529DC8-5470-46F1-BC0A-DC1F86D6B68FQ36171561-5D21C0F1-7976-4305-868F-DA9C5C790386Q36797491-EA4A98A9-A7C3-4B43-AF0F-51012AA5D969Q36870723-5C0A8B8F-3A99-429C-83EE-F4C622A7521AQ37346929-75770384-B5CA-4161-A494-453DAC74C283Q39784056-1C237698-4A40-4591-8647-DE274BFE98D4Q40241129-9B8B20CB-CEB9-490A-92F9-52A4A4642A0FQ41918906-CB2077B4-A9EE-4A72-A850-DEE34221C7B8Q42872165-F8F6CF1E-F3BB-4AB6-914C-0CFE6868E3B7Q43008604-657581B7-A0C4-4672-B87B-43D8C1ED7B76Q43865009-0C0068B3-7359-4ADC-AC8C-0EC081FD852EQ43895985-B93172AE-6445-414F-8DB6-2EBE8050D7A0
P2860
description
1995 nî lūn-bûn
@nan
1995年の論文
@ja
1995年論文
@yue
1995年論文
@zh-hant
1995年論文
@zh-hk
1995年論文
@zh-mo
1995年論文
@zh-tw
1995年论文
@wuu
1995年论文
@zh
1995年论文
@zh-cn
name
Clinical pharmacokinetics of rifabutin.
@en
type
label
Clinical pharmacokinetics of rifabutin.
@en
prefLabel
Clinical pharmacokinetics of rifabutin.
@en
P1476
Clinical pharmacokinetics of rifabutin
@en
P2093
M H Skinner
P304
P356
10.2165/00003088-199528020-00003
P577
1995-02-01T00:00:00Z
P5875
P6179
1037710882